# US 2016/0256488 A1 · Reducing Immune Tolerance Induced by PD-L1

> Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt

- Number: US 2016/0256488 A1
- Document ID: US20160256488A1
- Status: Published application
- Kind: A1
- Application number: 15/093,643
- Filed: 2016-04-07
- Published: 2016-09-08
- Earliest claimed: 2015-03-02
- Assignees: SIDANSAI Biotechnology CO., LTD
- Applicants: SiDanSai Biotechnology CO.,LTD
- Inventors: Zhao Wu
- Web page: https://patentgrep.com/patent/US20160256488A1

## CPC

- C07K 16/30: from tumour cells
- A61K 40/11: T-cells, e.g. tumour infiltrating lymphocytes [TIL] or regulatory T [Treg] cells; Lymphokine-activated killer [LAK] cells
- A61K 40/31: Chimeric antigen receptors [CAR]
- A61K 40/4211: {CD19 or B4}
- A61P 3/04: Anorexiants; Antiobesity agents
- A61P 35/00: Antineoplastic agents
- A61P 37/02: Immunomodulators
- A61P 37/04: Immunostimulants
- A61P 37/06: Immunosuppressants, e.g. drugs for graft rejection
- A61P 43/00: Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
- C07K 14/70503: {Immunoglobulin superfamily}
- C07K 14/7051: {T-cell receptor (TcR)-CD3 complex}
- C07K 14/70521: {CD28, CD152}
- C07K 16/2803: {against the immunoglobulin superfamily}
- C12N 5/0636: {T lymphocytes}
- C12N 5/0638: {Cytotoxic T lymphocytes [CTL] or lymphokine activated killer cells [LAK]}
- C07K 2319/00: Fusion polypeptide
- C07K 2319/02: containing a signal sequence
- C07K 2319/03: containing a transmembrane segment
- C12N 2510/02: Cells for production
- C07K: PEPTIDES (peptides in foodstuffs A23; obtaining protein compositions for foodstuffs, working-up proteins for foodstuffs A23J; preparations for medicinal purposes A61K; peptides containing beta-lactam rings C07D; cyclic dipeptides not having in their molecule any other peptide link than those which form their ring, e.g. piperazine-2,5-diones, C07D; ergot alkaloids of the cyclic peptide type C07D519/02; macromolecular compounds having statistically distributed amino acid units in their molecules, i.e. when the preparation does not provide for a specific; but for a random sequence of the amino acid units, homopolyamides and block copolyamides derived from amino acids C08G69/00; macromolecular products derived from proteins C08H1/00; preparation of glue or gelatine C09H; single cell proteins, enzymes C12N; genetic engineering processes for obtaining peptides C12N15/00; compositions for measuring or testing processes involving enzymes C12Q; investigation or analysis of biological material G01N33/00)
- A61K: PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES (devices or methods specially adapted for bringing pharmaceutical products into particular physical or administering forms A61J3/00; chemical aspects of, or use of materials for deodorisation of air, for disinfection or sterilisation, or for bandages, dressings, absorbent pads or surgical articles A61L; soap compositions C11D)
- A61P: SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- C12N: MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA (microbiological testing media C12Q1/00)

## Abstract

The present disclosure relates to compositions and methods for reducing immune tolerance associated with CAR T cell therapy. Embodiments of the present disclosure include isolated nucleic acid sequence comprising a nucleic acid sequence that encodes modified programmed cell death protein 1 (PD-1) and a nucleic acid sequence that encodes chimeric antigen receptor (CAR).

## Claims

### Claim 1

A pharmaceutical composition comprising an antitumor effective amount of a population of human T cells, wherein the human T cells of the population include human T cells that comprises a first nucleic acid sequence comprising a second nucleic acid sequence that encodes modified programmed cell death protein 1 (PD-1) and a third nucleic acid sequence that encodes chimeric antigen receptor (CAR), wherein the modified PD-1 and the CAR are expressed as gene products that are separate polypeptides.

### Claim 2 (depends on 1)

The pharmaceutical composition of claim 1, wherein an inhibitory effect of programmed death ligand 1 (PD-L1) on cytokine production of the human T cells of the population is less than an inhibitory effect of PD-L1 on cytokine production of human T cells that comprise the CAR and lack at least a part of the modified PD-1.

### Claim 3 (depends on 2)

The pharmaceutical composition of claim 2, wherein the modified PD-1 comprises a point mutation of Tyrosine residue 223 and a point mutation of Tyrosine reside 248 as compared to the intracellular part of wide-type PD-1.

### Claim 4 (depends on 2)

The pharmaceutical composition of claim 2, wherein the second nucleic acid sequence comprises the nucleic acid sequence of SEQ ID NO: 13.

### Claim 5 (depends on 2)

The pharmaceutical composition of claim 2, wherein the second nucleic acid sequence comprises substitution of at least two nucleotides as compared to a nucleic acid sequence encoding an intracellular part of wide-type PD-1, and wherein a polypeptide corresponding to the second nucleic acid comprises two amino acid point mutations of phosphorylation sites of wide-type PD-1.

### Claim 6 (depends on 1)

The pharmaceutical composition of claim 1, wherein an inhibitory effect of PD-L1 on cytokine production of the human T cells is at least 20% less than an inhibitory effect of PD-L1 on cytokine production of human T cells that comprise the CAR and lack at least a part of the modified PD-1.
